Company | LyondellBasell Industries N.V. |
Ticker | NYSE: LYB |
Reporting Period | Q2 2026 (quarter ended June 30, 2026) |
Earnings Date | July 31, 2026 — Before Market Open | Conference Call 11:00 AM ET |
Prepared | July 30, 2026 |
Sector ETF Benchmark | XLB (Materials Select Sector SPDR) |
Key Takeaway: The setup is skewed to beat — consensus at ~$3.40 diluted operating EPS is a low bar relative to the structural tailwinds management flagged on the Q1 call, but the stock has already given back nearly all of its post-conflict rally, meaning the market is pricing in meaningful sequential deceleration; the single biggest swing factor is whether the $0.50/lb cumulative PE price increase announced for April/May actually flowed through to realized margins, and whether Bayport PO/TBA restarted on schedule.
Heading into Q2 2026 results, the bar for LYB looks achievable but not trivial. Consensus operating EBITDA of ~$1.78B and diluted operating EPS of ~$3.40 represent a massive sequential step-up from Q1’s $615M EBITDA and $0.49 EPS — a step-up that management explicitly guided for on May 1, citing 90% utilization targets in O&P Americas, 80% in O&P EAI, and a confident tone on price realization. The estimate trajectory has been broadly stable since the Q1 print (consensus EPS moved only modestly from $3.37 to $3.40), suggesting the Street has largely digested management’s bullish Q2 setup without adding further upside. The stock, however, has dramatically underperformed: LYB is down ~19% since Q1 earnings vs. XLB flat and SPY +3%, implying the market has grown skeptical of the durability of conflict-driven pricing — a dynamic confirmed by DOW’s Q2 print (reported July 23) which showed PE prices settling $0.15/lb lower in June and guided Q3 EBITDA down ~26% sequentially. The key wildcard is the Bayport PO/TBA restart (guided for end of Q2, ~$25M/week earnings drag while down) and whether the $0.50/lb PE price increase was fully realized before the June settlement, which DOW confirmed was $0.15/lb lower — if LYB captured the full April/May increase before the June rollback, Q2 EBITDA could surprise to the upside; if the June settlement hit harder than expected, the miss risk is real.
Key Takeaway: Consensus EBITDA of ~$1.78B implies a near-tripling sequentially from Q1’s $615M — a high absolute bar but one management explicitly guided toward; the bigger swing factor is O&P Americas EBITDA (consensus ~$1.07B), which hinges on PE price realization and operating rate execution, while I&D remains a wildcard given the Bayport outage.
KPI | Q1 2026 Actual | Q2 2025 Actual (Prior Year) | Q2 2026 Consensus Est. | YoY Change | Mgmt Guidance (Q1 Call) | Cons. vs. Guidance |
Net Sales ($B) | $7.20B | $7.66B | $9.16B | +19.6% YoY | Higher prices & volumes; 90% utilization O&P Americas | Directionally in line |
EBITDA – Operating ($B) | $0.615B | $0.715B | $1.780B | +149% YoY | Significant further sequential improvement across nearly all businesses | Directionally in line |
Diluted EPS – Operating ($) | $0.49 | $0.62 | $3.40 | +446% YoY | No specific EPS guidance; implied by EBITDA outlook | N/A |
EBITDA – O&P Americas ($B) | $0.327B | $0.318B | $1.070B | +236% YoY | Higher margins & volumes; 90% utilization; PE orders 20% above pre-war avg | Directionally in line |
EBITDA – O&P EAI ($M) | -$6M | $46M | $268M | +483% YoY | ~80% operating rates; polymer margins improving as higher costs passed through | Directionally in line |
EBITDA – I&D ($M) | $224M | $290M | $337M | +16% YoY | ~75% op. rates (Bayport down); favorable performance expected; $25M/wk drag from Bayport | Below potential (Bayport drag) |
EBITDA – APS ($M) | $58M | $40M | $43M | +7% YoY | Soft auto/durable demand; contractual pricing lags pressure margins near-term | Slightly below guidance tone |
EBITDA – Technology ($M) | $18M | $34M | $58M | +71% YoY | Improved results from licensing milestones; slightly below Q4 2025 levels | Directionally in line |
CapEx – Total ($M) | $269M | $539M | $297M | -45% YoY | ~$1.2B FY2026 guidance; capital discipline maintained | In line with FY pace |
Free Cash Flow ($M) | -$538M | -$188M | $553M | N/M | Intentional working capital build to capture market opportunities | FCF positive expected despite WC build |
Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of July 30, 2026. Q2 2026 consensus estimates are current as of the preparation date. YoY comparisons use Q2 2025 actuals.
Top KPI #1: EBITDA – Operating
Quarter | Reported ($M) | Consensus ($M) | Surprise % | Result |
Q1 2026 | $615M | $555M | +10.8% | BEAT |
Q4 2025 | $417M | $467M | -10.7% | MISS |
Q3 2025 | $835M | $760M | +9.9% | BEAT |
Q2 2025 | $715M | $751M | -4.8% | MISS |
Q1 2025 | $576M | $626M | -8.0% | MISS |
Q4 2024 | $689M | $762M | -9.6% | MISS |
Q3 2024 | $1,211M | $1,299M | -6.8% | MISS |
Q2 2024 | $1,373M | $1,393M | -1.4% | MISS |
Top KPI #2: Diluted EPS – Operating
Quarter | Reported ($) | Consensus ($) | Surprise % | Result |
Q1 2026 | $0.49 | $0.24 | +104.5% | BEAT |
Q4 2025 | -$0.26 | $0.12 | N/M | MISS |
Q3 2025 | $1.01 | $0.79 | +27.9% | BEAT |
Q2 2025 | $0.62 | $0.81 | -23.2% | MISS |
Q1 2025 | $0.33 | $0.49 | -32.4% | MISS |
Q4 2024 | $0.75 | $0.73 | +2.6% | BEAT |
Q3 2024 | $1.88 | $2.03 | -7.5% | MISS |
Q2 2024 | $2.24 | $2.25 | -0.2% | MISS |
Pattern: LYB has missed EBITDA consensus in 6 of the last 8 quarters, with beats concentrated in Q3 2025 and Q1 2026 (both conflict-driven); the Q1 2026 EPS beat of +104% was the largest in the series, driven by a severely depressed consensus baseline — the Q2 2026 consensus is far more elevated, making a repeat magnitude beat unlikely but a directional beat plausible if PE price realization exceeded the June settlement.
Source: Visible Alpha Consensus and Actuals Data.
Key Takeaway: Management’s tone shifted decisively bullish on the Q1 2026 call (May 1), characterizing the Middle East conflict disruption as lasting “multiple quarters, definitely not months” and announcing cumulative $0.50/lb PE price increases for April/May; no formal guidance revisions have been issued since, but DOW’s Q2 print (July 23) introduced a cautionary note — a $0.15/lb June PE price settlement and Q3 EBITDA guided ~26% below Q2 — which may temper LYB’s Q3 outlook language.
Metric | Initial Guidance (Q1 2026 Earnings Call, May 1, 2026) | Revised Guidance | Current Consensus | Note |
O&P Americas Operating Rate | 90% utilization of nameplate capacity in Q2 | — | Implied in EBITDA consensus | No post-earnings revision; DOW ran 84% in Q2 due to planned maintenance — LYB targeted higher |
O&P EAI Operating Rate | ~80% across segment in Q2 | — | Implied in EAI EBITDA consensus of $268M | No revision; European asset sale (4 sites to AEQUITA, completed May 1) reduces EAI scope going forward |
I&D Operating Rate | ~75% in Q2 due to Bayport PO/TBA outage; restart targeted end of Q2 | — | Consensus I&D EBITDA $337M | Bayport drag ~$25M/week while down; restart timing is key variable for Q2 I&D result |
PE Price Increases | Cumulative $0.50/lb in April + May; $0.30 confirmed in April, $0.20 announced for May | — | Embedded in O&P Americas consensus | DOW confirmed $0.15/lb June settlement (down); LYB Q2 realization depends on timing of June rollback vs. April/May gains |
PP Spread Increases | $0.10/lb spread increases in both April and May | — | Embedded in O&P Americas consensus | PP characterized as “sleeping giant”; 15-20% operating rate improvement opportunity cited |
FY2026 CapEx | ~$1.2B (unchanged from Q4 2025 guidance) | — | $1.166B consensus | No revision; capital discipline maintained; consensus slightly below guidance |
FY2026 Effective Tax Rate | 15%–20% (revised up from ~10% at Q4 2025 call, reflecting improved earnings outlook) | — | Embedded in EPS consensus | ↑ Raised at Q1 2026 earnings call; higher earnings base drives higher effective rate |
Working Capital | Intentional build in Q2 to capture market opportunities from higher prices and operating rates | — | FCF consensus $553M for Q2 | WC build will be a headwind to FCF; management flagged this explicitly on Q1 call |
Key Takeaway: Q2 2026 EBITDA estimates have been essentially stable since the Q1 print ($1.775B now vs. $1.775B at baseline), suggesting the Street fully priced in management’s bullish Q2 setup immediately after the May 1 call; however, FY2026 EBITDA estimates have been revised up sharply (+17%) from $5.0B to $5.9B since the Q1 print, reflecting the structural re-rating of the conflict-driven cycle — the risk is that DOW’s Q3 guide signals the peak has passed, which could trigger FY estimate cuts post-Q2.
KPI (Period) | Estimate at May 6, 2026 (+5 Days Post Q1 Print) | Current Consensus (Jul 30, 2026) | Estimate Δ (%) | Initial Guidance (Q1 2026 Call) | Current Guidance | Guidance Δ | Cons. vs. Guidance (%) |
EBITDA – Operating (Q2 2026) | $1,775M | $1,780M | +0.3% | Significant sequential improvement; 90% O&P Americas utilization | Unchanged | — | Directionally in line |
Diluted EPS – Operating (Q2 2026) | $3.37 | $3.40 | +0.9% | No specific EPS guidance | N/A | — | N/A |
Net Sales (Q2 2026) | $9,380M | $9,158M | -2.4% | Higher prices and volumes | Unchanged | — | Directionally in line |
EBITDA – Operating (FY2026) | $5,857M | $4,998M | -14.6% | No FY EBITDA guidance; $1.5B recurring EBITDA target by 2028 (VEP) | Unchanged | — | N/A (no FY guidance) |
Diluted EPS – Operating (FY2026) | $10.42 | $8.30 | -20.3% | No FY EPS guidance | N/A | — | N/A |
Net Sales (FY2026) | $35,112M | $33,050M | -5.9% | No FY revenue guidance | N/A | — | N/A |
Note: The FY2026 estimate revision shows a notable downward move from the immediate post-Q1 baseline — the May 6 snapshot captured peak optimism right after management’s bullish Q1 call, while current consensus has moderated as DOW’s Q2 results (July 23) signaled a June PE price settlement of -$0.15/lb and guided Q3 EBITDA ~26% below Q2. Q2 2026 estimates, however, have been remarkably stable (+0.3% EBITDA, +0.9% EPS), confirming the Street locked in the Q2 setup immediately post-Q1 print and has not materially revised since. The key post-Q2 earnings risk is whether FY estimates face further cuts if management guides Q3 conservatively in line with DOW’s tone.
Source: Visible Alpha Consensus and Actuals Data.
Key Takeaway: LYB has dramatically underperformed since Q1 earnings — down ~19.4% vs. XLB +0.6% and SPY +2.9% — driven almost entirely by multiple compression and sentiment deterioration as the market grew skeptical of conflict-driven pricing durability; the stock’s de-rating from ~$75 to ~$60 has created a low-bar setup heading into Q2, but DOW’s Q3 guide suggests the earnings peak may be Q2, limiting re-rating potential.
[Image not found: gs://implied-user-data-prod/conversations/yhua@lumosity.ai/projects/_default/history/2e69f751-a6c5-4801-b698-46dbbd55fdb2/plotly_charts/52ef3fd4-4ca8-4761-9d63-7069ddb1239a.json]
LYB vs XLB (Materials ETF) vs S&P 500 — Indexed to 100 at Q1 2026 Earnings Date (May 1, 2026). Source: Stock Price Data.
Performance Summary (May 1 – July 30, 2026):
Series | Price at Earnings (5/1/26) | Price at 7/30/26 | Return Since Earnings |
LYB | $74.99 | $60.44 | -19.4% |
XLB (Materials ETF) | $51.35 | $51.64 | +0.6% |
S&P 500 (SPY) | $720.65 | $741.69 | +2.9% |
Key events driving the underperformance: LYB peaked at ~$77.76 on May 5 (4 days post-earnings) before a sustained sell-off through late June, reaching a trough of ~$52.58 on July 1 (-30% from earnings). The stock partially recovered in mid-July (to ~$62) before settling around $60. The sell-off was driven by: (1) growing market skepticism that the $0.50/lb PE price increase would fully stick through Q2; (2) DOW’s Q2 print on July 23 confirming a $0.15/lb June settlement and guiding Q3 EBITDA ~26% below Q2; and (3) broader materials sector weakness as macro uncertainty weighed on cyclicals. The July 7 LYB/Mondelez sustainable packaging announcement provided a brief +3.1% lift but did not change the trend. At $60, LYB trades at a significant discount to its pre-conflict levels and to the implied mid-cycle value management has articulated.
Source: Stock Price Data (Yahoo Finance). Sector ETF: XLB (Materials Select Sector SPDR) — appropriate for LYB’s specialty chemicals / materials sub-sector.
Key Takeaway: The most important development since Q1 earnings is DOW’s Q2 2026 print (July 23), which confirmed the conflict-driven PE pricing peak was Q2 and guided Q3 EBITDA ~26% lower sequentially — a direct read-through that the market has already priced into LYB’s stock (-19% since earnings) and that sets a cautious tone for LYB’s Q3 guidance language tomorrow.
Key Takeaway: Peers reporting Q1 2026 results (May 2026) uniformly flagged a strong Q2 2026 setup driven by conflict-driven supply tightness, aggressive price increases, and high operating rates — all consistent with LYB’s own Q1 guidance; DOW’s actual Q2 2026 print (July 23) then confirmed the strong quarter but introduced a critical caveat: the June PE price settlement of -$0.15/lb signals Q2 was the peak, and Q3 will see meaningful sequential deceleration.
Note: Only commentary about Q2 2026 (the current reporting quarter) is included below. Q1 2025 results commentary and prior-quarter retrospectives are excluded. Peers included: DOW (Q2 2026 actual results), WLK, HUN, EMN, OLN, CE (all Q1 2026 calls with Q2 2026 forward guidance).
Relevance to LYB: DOW is LYB’s closest peer in polyethylene and polyolefins; its Q2 actual results are the single most important read-through for LYB’s Q2 print.
Relevance to LYB: WLK is a direct PE and PVC competitor with a similar North American ethane-advantaged cost structure; its Q2 2026 setup commentary is highly relevant to LYB’s O&P Americas segment.
Relevance to LYB: HUN’s MDI/polyurethanes business overlaps with LYB’s I&D segment (PO/polyols); its commentary on Q2 demand and pricing is a read-through for LYB’s I&D and APS segments.
Relevance to LYB: EMN’s Chemical Intermediates segment (olefins, acetyls) overlaps with LYB’s I&D segment; its commentary on Q2 pricing and supply tightness is a read-through for LYB’s acetyls and oxyfuels businesses.
Relevance to LYB: OLN’s chlor-alkali and epoxy businesses overlap with LYB’s I&D segment; its commentary on supply tightness and pricing momentum is a read-through for LYB’s I&D chemicals businesses.
Relevance to LYB: CE’s Acetyl Chain (acetic acid, VAM, methanol) overlaps with LYB’s I&D acetyls business; its commentary on Q2 pricing and supply dynamics is a read-through for LYB’s acetyls segment.
Peer | Report Date | Q2 2026 Signal | Key LYB Read-Through | Bullish / Cautious |
DOW | Jul 23, 2026 (Q2 actual) | Q2 EBITDA $2.3B; PE prices +40% YoY; Q3 guided -26% sequential on June $0.15/lb settlement | Q2 was peak; June settlement is key variable for LYB Q2 margin realization; Q3 will decelerate | Mixed (Q2 strong, Q3 cautious) |
WLK | May 5, 2026 (Q1 call) | PE at full rates; $0.30 April increase achieved; $0.20 May announced; 2026 outlook improved meaningfully | Strong O&P Americas setup; natural gas tailwind in Q2; supply disruptions to persist through 2026 | Bullish |
HUN | May 1, 2026 (Q1 call) | Q2 demand stronger than expected; MDI sold out; pre-buying activity; June a “wildcard” | I&D/APS demand solid; Saudi JV logistics headwind; demand destruction risk in H2 | Cautiously bullish |
EMN | May 1, 2026 (Q1 call) | CI prices +20% sequential; methanol doubled; quantity shortage not yet fully felt; June wildcard | I&D acetyls/oxyfuels pricing strong; auto/durables still weak (APS headwind) | Bullish on I&D; cautious on APS |
OLN | May 8, 2026 (Q1 call) | Q2 EBITDA guided $160-200M; caustic +$185/ton; 6-9% global vinyls capacity offline | I&D chemicals pricing momentum; U.S. cost advantage durable even with ceasefire talk | Bullish |
CE | May 6, 2026 (Q1 call) | April was pricing high watermark; China prices moderating; H2 assumes supply chain unwind | I&D acetyls Q2 strong but peak; H2 moderation risk; end-use demand still low | Cautious on H2 |
Key Takeaway: The only notable open-market transaction is a discretionary sale of 10,000 shares by EVP Jeffrey Kaplan on May 13 — executed near the post-earnings peak (~$73-75) and before the stock’s subsequent -19% decline — which is worth flagging; all other activity is routine director equity compensation grants with no directional signal.
Name | Title | Transaction Type | Shares | Date | Note |
Kaplan, Jeffrey A. | EVP, Chief PC, Legal & Corporate Officer | Open Market Sale | 10,000 shares | May 13, 2026 | Discretionary open-market sale; executed ~12 days post-Q1 earnings near the post-conflict peak; no 10b5-1 plan indicated in filing |
AIGRAIN, Jacques | Director | Equity Grant (Award) | 4,437 shares | May 21, 2026 | Annual director equity compensation; routine; no directional signal |
Benet, Lincoln E. | Director | Equity Grant (Award) | 2,321 shares | May 21, 2026 | Annual director equity compensation; routine |
Buchanan, Robin W.T. | Director | Equity Grant (Award) | 2,321 shares | May 21, 2026 | Annual director equity compensation; routine |
Chase, Anthony R. | Director | Equity Grant (Award) | 2,321 shares | May 21, 2026 | Annual director equity compensation; routine |
Dudley, Robert W. | Director | Equity Grant (Award) | 2,321 shares | May 21, 2026 | Annual director equity compensation; routine |
Farley, Claire S. | Director | Equity Grant (Award) | 2,321 shares | May 21, 2026 | Annual director equity compensation; routine |
Griffin, Rita E. | Director | Equity Grant (Award) + Tax Withholding | 2,321 granted / 639 withheld | May 21-22, 2026 | Annual grant; 639 shares withheld for tax obligation — not a discretionary sale |
Hanley, Michael Sean | Director | Equity Grant (Award) | 2,321 shares | May 21, 2026 | Annual director equity compensation; routine |
Kamsky, Virginia A. | Director | Equity Grant (Award) + Tax Withholding | 2,321 granted / 100 withheld (May); 561 granted / 100 withheld (Jun) | May 21 & Jun 30, 2026 | Routine annual grant plus supplemental grant; tax withholding disposals are obligation-driven |
Karlin, Bridget E. | Director | Equity Grant (Award) + Tax Withholding | 2,321 granted / 73 withheld (May); 615 granted / 73 withheld (Jun) | May 21 & Jun 30, 2026 | Routine annual grant plus supplemental grant; tax withholding disposals are obligation-driven |
Manifold, Albert Jude | Director | Equity Grant (Award) | 2,321 shares | May 21, 2026 | Annual director equity compensation; routine |
Assessment: The only transaction warranting attention is EVP Kaplan’s 10,000-share open-market sale on May 13 — a discretionary sale executed near the post-Q1 earnings peak, with no 10b5-1 plan indicated. While a single executive sale is not conclusive, the timing (12 days post-earnings, near the $73-75 range that proved to be the cycle high) is notable in retrospect. No open-market buys were recorded in the period, and no clustered executive selling pattern is present. All other activity is routine annual director equity compensation.
Source: Insider Transaction Data (SEC Form 4 filings).